Negative selection of B lymphocytes: A novel role for innate immunity

Immunological Reviews

Volumn 173, Issue , 2000, Pages 120-130

  Gommerman, Jennifer L ^a   Carroll, Michael C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4;

AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL SELECTION; COMPLEMENT ACTIVATION; HOST RESISTANCE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; IMMUNE TOLERANCE; IMMUNITY, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOID TISSUE; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; RECEPTORS, COMPLEMENT;

EID: 0033954220     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2000.917312.x     Document Type: Review

References (79)

1. 1. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbour Sym Quant Biol 1989;54: 1-13.
2. 2. Janeway CA Jr. The road less traveled: The role of innate immunity on the adaptive immune response. J Immunol 1998;161:539-544.
3. 3. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-353.
4. 4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
5. 5. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-54.
6. 6. Epstein J, Eichbaum Q, Sheriff S, Ezekowitz R. The collectins in innate immunity. Curr Opin Immunol 1996;8:29-35.
7. 7. Law SK, Lichtenberg NA, Levine RP. Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 1980;77:7194-7198.
8. 8. Kinoshita T, Fujita T, Tsunoda R. Expression of complement receptors CR1 and CR2 on murine follicular dendritic cells and B lymphocytes. In: Imai Y, Tew JW, Hoefsmit ECM, eds. Dendritic cells in lymphoid tissues. Vol 2. Amsterdam: Elsevier; 1991. p. 271.
9. 9. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992;149:2841-2850.
10. 10. Matsumoto AK, Kopicky-Bird J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte containing complement receptor type 2 and CD19. J Exp Med 1991;173:55-64.
11. 11. Krop I, Shaffer AL, Fearon DT, Schlissel MS. The signaling activity of murine CD19 is regulated during B cell development. J Immunol 1996;157:48-56.
12. 12. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256:105-107.
13. 13. Dempsey P, Allicson M, Akkaraju S, Goodnow C, Fearon D. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348-350.
14. 14. Lay WH, Nussenzweig V. Receptors for complement on leukocytes. J Exp Med 1968;128:991-1009.
15. 15. Pepys MB. Role of complement in induction of the allergic response. Nature: New Biology 1972;237:157-159.
16. 16. Papamichail M, Gutierrez C, Embling P, Johnson P, Holborow EJ, Pepys MB. Complement dependence of localization of aggregated IgG in germinal centers. Scand J Immunol 1975;4:343-347.
17. 17. Bitter-Suermann D, Burger R. C3 Deficiencies. Curr Top Microbiol Immunol 1989;153:223-233.
18. 18. O'Neil KM, Ochs HD, Heller SR, Cork LC, Morris JM, Winkelstein JA. Role of C3 in humoral immunity: defective antibody production in C3-deficient dogs. J Immunol 1988;140:1939-1945.
19. 19. Jackson CG, Ochs HD, Wedgewood RJ. Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med 1979;300:1124-1129.
20. 20. Fischer M, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996;157:549-556.
21. 21. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-149.
22. 22. Wiersma EJ, Kinoshita T, Heyman B. Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur J Immunol 1991;21:2501-2506.
23. 23. Hebell T, Ahearn JM, Fearon DT. Supression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991;254:102-105.
24. 24. Typhronitis G, et al. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol 1991;147:224-230.
25. 25. Kurtz CB, O'Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 1990;144:3581-3591.
26. 26. Molina H, Kinoshita T, Inoue K, Carel J-C, Holers VM. A molecular and immunochemical characterization of mouse CR2. J Immunol 1990;145:2974-2983.
27. 27. Kalli KR, Fearon DT. Binding of C3b and C4b by the CR1-like site in murine CR1. J Immunol 1994;152:2899-2903.
28. 28. Molina H, et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 1996;93:3357-3361.
29. 29. Ahearn J, et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996;4:251-262.
30. 30. Fischer MB, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998;280:582-585.
31. 31. Fang Y, Xu C, Fu Y, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998;160:5273-5279.
32. 32. Norvell A, Mandik L, Monroe JG. Engagement of the antigen receptor on immature murine B lymphocytes results in death by apoptosis. J Immunol 1995;154:4404-4413.
33. 33. Carsetti R, Kohler G, Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995;181:2129-2140.
34. 34. Melamed D, Benschop RJ, Cambier JC, Nemazee DI. Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. Cell 1998;92:173-182.
35. 35. Chen C, et al. The site and stage of anti-DNA B-cell deletion. Nature 1995;373:252-255.
36. 36. Goodnow C, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 1995;59:279-369.
37. 37. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93:2264-2271.
38. 38. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991;353:765-769.
39. 39. Goodnow CG, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988;334:676-682.
40. 40. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines the thresholds for negative selection. Immunity 1995;2:13-24.
41. 41. Cornall RJ, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
42. 42. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19 regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997;186:1923-1931.
43. 43. Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994;179:125-134.
44. 44. Cooke MP, et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med 1994;179:425-438.
45. 45. Prodeus AP, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998;9:721-731.
46. 46. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from recirculating B cell repertoire. Nature 1994;371:389-395.
47. 47. Cotran RS. Kumar V, Robbins SL, Pathologic basis of disease. 5th ed. Philadelphia: WB Saunders; 1994.
48. 48. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-1306.
49. 49. Takahashi T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.
50. 50. Watanabe FR, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
51. 51. Van Parijs L, Ibraghimov A, Ak A. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996;4:321-328.
52. 52. Jacobson BA, Panka DJ, Nguyen K-A, Erikson J, Abbas AK, Marshak-Rothestein A. Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Immunity 1995;3:509-519.
53. 53. Rothstein TL, et al. Protection against Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995;374:163-165.
54. 54. Garrone P, Neidardt EM, Garcia E, Gailbert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995;182:1265-1273.
55. 55. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40-Fas (CD95)-ligand modulated by the B cell antigen receptor. Cell 1996;87:319-329.
56. 56. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996;274:798-801.
57. 57. Tsui KW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993;4:124-129.
58. 58. Hibbs ML, et al. Multiple defects in the immune system of lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-311.
59. 59. Walport MJ, Morgan BP. Complement deficiency and disease. Immunol Today 1991;12:301-306.
60. 60. Dias Da Silva W, Eisele JW, Lepow IH. Complement as a mediator of inflammation. III. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C3. J Exp Med 1967;126:1027-1048.
61. 61. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-347.
62. 62. Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-59.
63. 63. Carroll MC. The lupus paradox. Nat Genet 1998;19:3-4.
64. 64. Bickerstaff MCM, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity Nat Med 1999;5:694-697.
65. 65. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic keratinocytes. J Immunol 1997;158:4525-4528.
66. 66. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
67. 67. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
68. 68. Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986;315:488-495.
69. 69. Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol 1988;140:3066-3072.
70. 70. Quigg RJ, Alexander JJ, Lo CF, Lim A, He C, Holers VM. Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol 1997;159:2438-2444.
71. 71. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-1054.
72. 72. Mitchell DA, et al. C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol 1999;162:5676-5679.
73. 73. Takahashi K, et al. Mouse complement receptors type 1 (CR1; CD35) and type 2 (Cr2; CD21) expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997;159:1557-1569.
74. 74. Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol (In press).
75. 75. Kantor AB, Herzenberg LA. Origin of murine B cell lineages. Annu Rev Immunol 1993;11:501-538.
76. 76. Baumgarth N, Herman OC, Jager GC, Brown L, Herzenberg LA. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc Natl Acad Sci USA 1999;96:2250-2255.
77. 77. Lorber M, Kra-oz Z, Guilbrud B, Shoenfeld Y. Natural (antiphospholipid-PDH,-DNA) autoantibodies and their physiologic serum inhibitors. Isr J Med Sci 1995;31:31-35.
78. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 1989;10:364-368.
79. 79. Paul E, Carroll MC. SAP-less chromatin triggers systemic lupus erythematosus. Nat Med 1999;5:607-608.